Please login to the form below

Not currently logged in
Email:
Password:

anxiety

This page shows the latest anxiety news and features for those working in and with pharma, biotech and healthcare.

Moderna CEO makes case for firm’s lofty valuation

Moderna CEO makes case for firm’s lofty valuation

Moderna’s record-breaking $604m IPO last year was followed by a steep decline in its shares, which contributed to the anxiety about biotech sector financing overall in 2019, although Bancel

Latest news

More from news
Approximately 1 fully matching, plus 138 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Galbraith is concerned about the rise in reported anxiety and mental health problems in young people, with young women most vulnerable.

  • The Patient Safety Challenge The Patient Safety Challenge

    There were anxieties about how reporting could affect their reputations and career prospects.

  • Finding the patient voice Finding the patient voice

    This data provided the big picture about what motivates people to join clinical trials, their anxieties and their experiences. ... we should communicate with them, depending on their needs and anxieties.

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    The pursuit of pain relief is nowhere near over and many companies and institutions are chasing answers to reduce the impact of chronic pain and its corrosive byproducts: anxiety, fatigue, depression

  • Mining for results Mining for results

    it takes a good amount of their anxiety away,” he explains.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Dr Niall Murphy and Pierre Schwich join Pharnext Dr Niall Murphy and Pierre Schwich join Pharnext

    Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity

  • Turing names Eliseo Salinas as head of R&D Turing names Eliseo Salinas as head of R&D

    Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics